You finally have investor interest. A couple of angels like the idea, one says “We usually do SAFEs,” another asks if you’re open to a convertible note, and suddenly you’re deep in legal blog posts at ...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results